What is endocrine therapy refractory?
Endocrine therapies Fulvestrant is an selective estrogen receptor downregulator (SERD) used in the management of metastatic hormone receptor-positive breast cancer in both the first- and subsequent-line settings.
What are endocrine therapies?
Treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels.
What drugs are endocrine therapy?
4. Hormone therapy drugs
- Aromatase inhibitors (letrozole, anastrozole and exemestane)
- Goserelin (Zoladex)
- Leuprorelin (Prostap)
- Fulvestrant (Faslodex)
What is endocrine adjuvant therapy?
Abstract. Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor-positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer. For decades, 5 years of tamoxifen has been the standard treatment.
What is hormone refractory disease?
Listen to pronunciation. (HOR-mone-reh-FRAK-tor-ee) In medicine, describes a disease or condition that does not respond to treatment with hormones. Also called hormone-resistant.
What is ESR1 mutation?
Mutations in the estrogen receptor gene (ESR1) are acquired frequently in metastatic hormone receptor–positive breast cancer (1, 2). Mutations are selected in the cancer as a mechanism of clinical acquired resistance to prior aromatase inhibitor therapy, acquired relatively rarely through tamoxifen (3, 4).
What are side effects of hormone therapy?
What Are the Side Effects of Hormone Replacement Therapy?
- Breast swelling or tenderness.
- Mood changes.
- Vaginal bleeding.
Is Tamoxifen considered endocrine therapy?
Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival.
Why are breast cancer cells resistant to endocrine therapy?
Tumor cells can develop resistance to endocrine therapy, a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptors and growth factors was considered to be a crucial factor contributing to endocrine resistance.
How is endocrine resistance related to de novo resistance?
Endocrine Resistance. Endocrine resistance occurs due to both de novo and acquired resistance. De novo resistance happens when endocrine resistance develops at the beginning of treatment, while acquired resistance occurs by non-responsive or stimulated growth after endocrine therapy .
Which is the best book on endocrine resistance?
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e37. 1 From the Department of Pharmacology and Toxicology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
Which is the most common type of endocrine resistance?
However, a significant number of cases exhibit de novo or acquired endocrine resistance. While other clinical subtypes of breast cancer (HER2+, triple-negative) have disproportionately higher rates of mortality, ER+ breast cancer is responsible for at least as many deaths because it is the most common subtype.